Efficacy and Safety of Carfilzomib at 56mg/m2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study

This article has no abstract
Epistemonikos ID: 10c1bf78a213f924be02da81ef31f009f469700c
First added on: Feb 11, 2025